136207-23-3
Chemical Structure
BIM-26226
- CAS No.: 136207-23-3
- Formula:C49H63F5N12O10
- Molecular Weight:1075.09
IUPAC Name: methyl ((R)-2-amino-3-(perfluorophenyl)propanoyl)-L-glutaminyl-L-tryptophyl-L-alanyl-L-valyl-D-alanyl-L-histidyl-L-leucinate
InChIKey: ZCTCXFYZJYFGAQ-ZZXDJSGYSA-N
SMILES: CC(C)C[C@@H](C(OC)=O)NC([C@H](CC1=CNC=N1)NC([C@@H](C)NC([C@H](C(C)C)NC([C@H](C)NC([C@H](CC2=CNC3=CC=CC=C23)NC([C@H](CCC(N)=O)NC([C@@H](CC4=C(F)C(F)=C(F)C(F)=C4F)N)=O)=O)=O)=O)=O)=O)=O
Biological Activity: BIM-26226 is a selective gastrin-releasing peptide receptor (GRPR) (IC50 = 6 nM) and bombesin receptor (BN receptor) antagonist. BIM-26226 antagonizes BN- or GRP-stimulated amylase release with IC50 values of 0.3 nM and 0.2 nM, respectively. BIM-26226 is specific for the GRP-preferring BN receptor subtype with no interference with GRP receptor system. BIM-26226 can induce the synthesis of somatostatin receptor but has no significant effect on tumor growth[1][2][3][4].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
BIM-26226 | 98.73% | BIM-26226 is a selective gastrin-releasing peptide receptor (GRPR) (IC50 = 6 nM) and bombesin receptor (BN receptor) antagonist. BIM-26226 antagonizes BN- or GRP-stimulated amylase release with IC50 values of 0.3 nM and 0.2 nM, respectively. BIM-26226 is specific for the GRP-preferring BN receptor subtype with no interference with GRP receptor system. BIM-26226 can induce the synthesis of somatostatin receptor but has no significant effect on tumor growth. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Dietrich JB, et, al. Effects of BIM26226, a potent and specific bombesin receptor antagonist, on amylase release and binding of bombesin-like peptides to AR4-2J cells. Regul Pept. 1994 Oct 21;53(3):165-73. [Content Brief]
- [2]. Damgé C, et, al. Effect of the gastrin-releasing peptide antagonist BIM 26226 and lanreotide on an acinar pancreatic carcinoma. Eur J Pharmacol. 1998 Apr 17;347(1):77-86. [Content Brief]
- [3]. Gouyon B, et al. In-vivo effect of somatostatin analog, lanreotide, and/or grp antagonist, bim-26226, on the growth of colon-cancer peritoneal carcinomatosis in the rat. Int J Oncol. 1995 Nov;7(5):1167-73. [Content Brief]
- [4]. Bold RJ, et al. Bombesin stimulates the in vitro growth of a human gastric cancer cell line. J Cell Physiol. 1994 Dec;161(3):519-25. [Content Brief]
